No Data
No Data
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a good week for Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SZSE:002223) shareholders, because the company has just released its latest first-quarter results, and the shares gained 3
Yuyue Healthcare (002223): Short-term fluctuations due to base change are optimistic about innovation and overseas driving growth
Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 7.972 billion yuan (+12.25%) and net profit to mother of 2,396 billion yuan (+50.21%), deducted
Yuyue Medical (002223) 2023 Report 2024 Quarterly Report Comment: Performance is in line with expectations, and the blood sugar business is gradually accelerating
Summary of key investment points: In 2023, the company achieved operating income of 7.972 billion yuan (+12.3%, same ratio, same below), realized net profit to mother of 2,396 billion yuan (+50.2%), and realized net profit deducted from non-mother 1
Yuyue Healthcare (002223): Product structure optimization, gross margin increased significantly
Conclusions and suggestions: Company performance: The company released financial reports for 2023 and 24Q1, achieved revenue of 7.97 billion yuan in 2023, YOY +12.3%, recorded net profit of 2.4 billion yuan to mother, YOY+50.
Yuyue Medical (002223) 2023 Report and 2024 Quarterly Report Review: Performance is in line with expectations, domestic and overseas two-wheel drive
Incident: The company released the 2023 annual report and the 2024 quarterly report. In 23, the company achieved total operating revenue/net profit attributable to mother/net profit without return to mother of 79.72/23.96/1,836 billion yuan, an increase of 12 yuan over the previous year.
Yuyue Healthcare (002223): Under pressure from a high base, the growth rate is expected to grow steadily throughout the year
Introduction to this report: The performance is in line with expectations. The performance was outstanding in 2023, driven by sectors such as respiratory oxygen production and blood sugar. The growth rate of 2024Q1 is under pressure under pressure. It is expected to maintain steady growth throughout the year as the base declines, overseas expansion, and new product promotion.
No Data